Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Dermatology
•
Hidradenitis Suppurativa
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Pt has not responded to Humira or Cosentyx. Pt is declining to have any infusion options.
Related Questions
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
How do you approach managing nausea and GI side effects when initiating methotrexate?
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
Would you continue TNF-inhibitor in a patient with psoriatic arthritis who has had multiple nonmelanoma skin cancers requiring Mohs surgery?
Have you utilized JAK inhibitors in patients on dialysis?
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?